• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

确定多囊肾病患者重要的结局:一项国际名义群体技术研究。

Identifying patient-important outcomes in polycystic kidney disease: An international nominal group technique study.

机构信息

Department of Nephrology, Princess Alexandra Hospital.

Australasian Kidney Trials Network, University of Queensland.

出版信息

Nephrology (Carlton). 2019 Dec;24(12):1214-1224. doi: 10.1111/nep.13566. Epub 2019 May 2.

DOI:10.1111/nep.13566
PMID:30663163
Abstract

AIM

Patients with autosomal dominant polycystic kidney disease (ADPKD) are at increased risk of premature mortality, morbidities and complications, which severely impair quality of life. However, patient-centered outcomes are not consistently reported in trials in ADPKD, which can limit shared decision-making. We aimed to identify outcomes important to patients and caregivers and the reasons for their priorities.

METHODS

Nominal group technique was adopted involving patients with ADPKD and caregivers who were purposively selected from eight centres across Australia, France and the Republic of Korea. Participants identified, ranked and discussed outcomes for trials in ADPKD. We calculated an importance score (0-1) for each outcome and conducted thematic analyses.

RESULTS

Across 17 groups, 154 participants (121 patients, 33 caregivers) aged 19 to 78 (mean 54.5 years) identified 55 outcomes. The 10 highest ranked outcomes were: kidney function (importance score 0.36), end-stage kidney disease (0.32), survival (0.21), cyst size/growth (0.20), cyst pain/bleeding (0.18), blood pressure (0.17), ability to work (0.16), cerebral aneurysm/stroke (0.14), mobility/physical function (0.12), and fatigue (0.12). Three themes were identified: threatening semblance of normality, inability to control and making sense of diverse risks.

CONCLUSION

For patients with ADPKD and their caregivers, kidney function, delayed progression to end-stage kidney disease and survival were the highest priorities, and were focused on achieving normality, and maintaining control over health and lifestyle. Implementing these patient-important outcomes may improve the meaning and relevance of trials to inform clinical care in ADPKD.

摘要

目的

常染色体显性多囊肾病(ADPKD)患者的过早死亡率、发病率和并发症风险增加,严重影响生活质量。然而,ADPKD 临床试验中并未一致报告以患者为中心的结局,这可能限制了共同决策。本研究旨在确定对患者和照护者重要的结局及其优先顺序的原因。

方法

采用名义小组技术,从澳大利亚、法国和韩国的 8 个中心有目的地选择 ADPKD 患者和照护者参与。参与者确定、排序并讨论了 ADPKD 临床试验中的结局。我们为每个结局计算了一个重要性得分(0-1),并进行了主题分析。

结果

在 17 个小组中,共有 154 名参与者(121 名患者,33 名照护者),年龄 19 至 78 岁(平均 54.5 岁),确定了 55 个结局。排名前 10 的结局为:肾功能(重要性得分 0.36)、终末期肾病(0.32)、生存(0.21)、囊肿大小/生长(0.20)、囊肿疼痛/出血(0.18)、血压(0.17)、工作能力(0.16)、脑动脉瘤/中风(0.14)、移动性/身体功能(0.12)和疲劳(0.12)。确定了 3 个主题:威胁正常的表象、无法控制和理解多种风险。

结论

对于 ADPKD 患者及其照护者,肾功能、延缓进展为终末期肾病和生存是最重要的优先事项,重点是实现正常化,并保持对健康和生活方式的控制。实施这些患者重要的结局可能会提高临床试验在 ADPKD 中的意义和相关性,从而为临床护理提供信息。

相似文献

1
Identifying patient-important outcomes in polycystic kidney disease: An international nominal group technique study.确定多囊肾病患者重要的结局:一项国际名义群体技术研究。
Nephrology (Carlton). 2019 Dec;24(12):1214-1224. doi: 10.1111/nep.13566. Epub 2019 May 2.
2
Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey.常染色体显性遗传多囊肾病临床试验的核心结局指标:国际德尔菲调查。
Am J Kidney Dis. 2020 Sep;76(3):361-373. doi: 10.1053/j.ajkd.2020.01.005. Epub 2020 Apr 28.
3
Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease.肾脏病-多囊肾病标准化结局(SONG-PKD):建立多囊肾病核心结局集的研究方案
Trials. 2017 Nov 23;18(1):560. doi: 10.1186/s13063-017-2298-4.
4
Identifying and integrating consumer perspectives in clinical practice guidelines on autosomal-dominant polycystic kidney disease.在常染色体显性多囊肾病临床实践指南中识别并整合患者观点。
Nephrology (Carlton). 2016 Feb;21(2):122-32. doi: 10.1111/nep.12579.
5
Patient and Caregiver Priorities for Outcomes in CKD: A Multinational Nominal Group Technique Study.慢性肾脏病结局评估的患者和照护者重点关注内容:一项多国名义群体技术研究。
Am J Kidney Dis. 2020 Nov;76(5):679-689. doi: 10.1053/j.ajkd.2020.03.022. Epub 2020 May 31.
6
Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Consensus Workshop.建立常染色体显性遗传性多囊肾病的核心结局集:肾脏病预后质量倡议-多囊肾病(SONG-PKD)共识研讨会报告。
Am J Kidney Dis. 2021 Feb;77(2):255-263. doi: 10.1053/j.ajkd.2020.05.024. Epub 2020 Aug 6.
7
Identifying Important Outcomes for Young People With CKD and Their Caregivers: A Nominal Group Technique Study.确定患有慢性肾脏病的年轻人及其照顾者的重要结局:名义小组技术研究。
Am J Kidney Dis. 2019 Jul;74(1):82-94. doi: 10.1053/j.ajkd.2018.12.040. Epub 2019 Mar 15.
8
Patient and Caregiver Priorities for Outcomes in Peritoneal Dialysis: Multinational Nominal Group Technique Study.腹膜透析结局的患者和照护者优先事项:多国名义群体技术研究。
Clin J Am Soc Nephrol. 2019 Jan 7;14(1):74-83. doi: 10.2215/CJN.05380518. Epub 2018 Dec 20.
9
'A sword of Damocles': patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study.“达摩克利斯之剑”:常染色体显性遗传多囊肾病(ADPKD)症状前检测的患者和照护者信念、态度和观点:一项焦点小组研究。
BMJ Open. 2020 Oct 10;10(10):e038005. doi: 10.1136/bmjopen-2020-038005.
10
Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review.多囊肾病患者随机试验报告的结局范围和变异性:系统评价。
Am J Kidney Dis. 2020 Aug;76(2):213-223. doi: 10.1053/j.ajkd.2019.12.003. Epub 2020 Mar 11.

引用本文的文献

1
Systematic Review of Patient and Caregiver Involvement in CKD Research.关于患者及照护者参与慢性肾脏病研究的系统评价
Kidney Int Rep. 2025 Mar 17;10(6):1657-1672. doi: 10.1016/j.ekir.2025.03.018. eCollection 2025 Jun.
2
Goals of Frail Older People Living With Chronic Kidney Disease: A Mixed Methods Study.老年慢性肾脏病患者的目标:一项混合方法研究
J Am Geriatr Soc. 2025 Jun;73(6):1742-1752. doi: 10.1111/jgs.19421. Epub 2025 Mar 5.
3
Validating the SONG-PKD Pain Instrument, a Core Outcome Measure for Pain in ADPKD.验证SONG-PKD疼痛评估工具,这是常染色体显性多囊肾病疼痛的一项核心结局指标。
Kidney Int Rep. 2024 Nov 17;10(2):447-456. doi: 10.1016/j.ekir.2024.11.015. eCollection 2025 Feb.
4
Nephrectomy in autosomal dominant polycystic kidney disease: a consensus statement of the ERA Genes & Kidney Working Group.常染色体显性多囊肾病的肾切除术:欧洲肾脏协会基因与肾脏工作组的共识声明
Nephrol Dial Transplant. 2025 Apr 28;40(5):1032-1054. doi: 10.1093/ndt/gfaf019.
5
Partnering with patients and caregivers to enrich research and care in kidney disease: values and strategies.与患者及护理人员合作,以丰富肾脏疾病的研究与护理:价值观与策略。
Clin Kidney J. 2023 Sep 13;16(Suppl 1):i57-i68. doi: 10.1093/ckj/sfad063. eCollection 2023 Sep.
6
Participant Perceptions in a Long-term Clinical Trial of Autosomal Dominant Polycystic Kidney Disease.常染色体显性多囊肾病长期临床试验中的参与者认知
Kidney Med. 2023 Jun 29;5(9):100691. doi: 10.1016/j.xkme.2023.100691. eCollection 2023 Sep.
7
What is 'successful rehabilitation'? A multi-stakeholder nominal group technique study to inform rehabilitation outcome measurement.“成功康复”是什么?一项多利益相关者名义小组技术研究,旨在为康复结果测量提供信息。
Clin Rehabil. 2023 Sep;37(9):1248-1259. doi: 10.1177/02692155231157181. Epub 2023 Feb 13.
8
A Step Ahead toward Measuring Pain in Autosomal Dominant Polycystic Kidney Disease (ADPKD).迈向测量常染色体显性多囊肾病(ADPKD)疼痛的新一步。
Clin J Am Soc Nephrol. 2023 Feb 1;18(2):160-162. doi: 10.2215/CJN.0000000000000042. Epub 2023 Jan 17.
9
Research priorities for autosomal dominant polycystic kidney disease: a UK priority setting partnership.常染色体显性遗传性多囊肾病研究重点:英国优先事项设定伙伴关系。
BMJ Open. 2022 Jun 15;12(6):e055780. doi: 10.1136/bmjopen-2021-055780.
10
Establishing a core outcome measure for pain in patients with autosomal dominant polycystic kidney disease: a consensus workshop report.建立常染色体显性多囊肾病患者疼痛的核心结局指标:一项共识研讨会报告
Clin Kidney J. 2021 Jul 6;15(3):407-416. doi: 10.1093/ckj/sfab110. eCollection 2022 Mar.